Resistant Hypertension Drug Development Pipeline Study, H1 2018 - ResearchAndMarkets.com

June 12, 2018

DUBLIN--(BUSINESS WIRE)--Jun 12, 2018--The “Resistant Hypertension: Drug Development Pipeline Study, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Resistant Hypertension pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Resistant Hypertension report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Resistant Hypertension industry.

10 companies are developing the pipeline for Resistant Hypertension. Of this, Idorsia Pharmaceuticals Ltd’s therapeutic candidate is likely to advance into Phase 3 in H1-2018.

Resistant hypertension is one of the potential causes for cardiovascular disease. The condition involves the patient to witness sustained high blood pressures. Despite administration of three or more anti-hypertensive therapies, the targeted pressure of 140/90 (systolic/ diastolic) is not attained.

Around half of the hypertension patients in the US have uncontrolled hypertension, of which around 12% to 15% possess resistant hypertension.

In addition, patients with resistant hypertension typically possess historical diabetes mellitus and chronic kidney condition, resulting in higher complexity.

Key Topics Covered:

1 Figures & Tables

2 Executive Summary

2.1 Disease Overview

2.2 Pipeline Snapshot

2.3 Pipeline Drugs by Phase

2.4 Pipeline Drugs by Company

2.5 Pipeline Drugs by Mechanism Of Action

3 Resistant Hypertension- Company wise Pipeline Analysis

3.1 Bayer Ag Pipeline, H1 2018

3.2 Idorsia Pharmaceuticals Ltd Pipeline, H1 2018

3.3 Ionis Pharmaceuticals, Inc Pipeline, H1 2018

3.4 Marina Biotech Inc Pipeline, H1 2018

3.5 Novartis Pharmaceuticals Pipeline, H1 2018

3.6 Sarfez Pharmaceuticals Inc Pipeline, H1 2018

3.7 Zumbro Discovery Inc Pipeline, H1 2018

4 Resistant Hypertension Drug Snapshots

4.1 IONIS-AGT-LRX Drug Details

4.2 Aprocitentan Drug Details

4.3 LHW090 Drug Details

4.4 SP20203 Drug Details

4.5 ZD100 Drug Details

4.6 IT 103 Drug Details

4.7 BAY sGCstim Drug Details

5 Recent Developments in Resistant Hypertension Pipeline

5.1 Janssen Biotech to Pay $230M In Hypertension Deal with Idorsia- December 2017

5.2 Marina Biotech Announces Agreement For Drug Development and Licensing With Autotelic Bio- January 2018

5.3 Evaluation FF Cardiovascular Outcome in TRH Vs Non-Trh- February 2018

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/63gssz/resistant?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180612006405/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/12/2018 03:19 PM/DISC: 06/12/2018 03:19 PM


Update hourly